GeoVax Labs, Inc.

GeoVax Labs reported a net loss of $4.43 million for Q2 2026, an improvement from $5.37 million in Q2 2025, but revenue from government contracts ceased. The company's cash and cash equivalents stood at $3.14 million as of June 30, 2026. GeoVax plans to initiate a Phase 3 clinical trial for its GEO-MVA mpox/smallpox vaccine candidate in late 2026 and a Phase 2 trial for Gedeptin® in 2027, while discontinuing its COVID-19 vaccine program. The company also noted that existing cash resources are sufficient only into September 2026, raising substantial doubt about its ability to continue as a going concern without additional funding.

GeoVax Labs, Inc. reported a net loss of $4.43 million, or $0.97 per share, for the second quarter of 2026, an improvement from a $5.37 million loss in the prior year. Revenue for the quarter was $0, following the termination of its BARDA contract in April 2025. The company continued to advance its GEO-MVA pivotal immunobridging study, with planned initiation in Q4 2026, and its Gedeptin® immuno-oncology program, while strategically discontinuing its GEO-CM04S1 COVID-19 vaccine candidate development.

GeoVax Labs, Inc. announced it received a notice from the Nasdaq Stock Market LLC on July 7, 2026, indicating non-compliance with the $2,500,000 minimum stockholders' equity requirement for continued listing. The company also did not meet alternative listing standards. GeoVax has until August 21, 2026, to submit a plan to regain compliance, and its common stock will continue to trade on Nasdaq under the symbol "GOVX" during this period.

GeoVax Labs, Inc. filed an S-1 registration statement for the resale of 7,639,967 shares of common stock by selling stockholders, following recent financing activities. The company announced a strategic reprioritization, discontinuing its GEO-CM04S1 COVID-19 vaccine candidate to focus resources on its lead programs, GEO-MVA and Gedeptin®. This decision was driven by the evolving COVID-19 vaccine market and a focus on programs with clearer regulatory pathways. GeoVax recently raised approximately $844,080 from a warrant exercise inducement and $2.7 million from a private placement of pre-funded and common warrants. The company continues to face operating losses and has received a "going concern" opinion from its auditors, with existing cash sufficient only into June 2026.

GeoVax Labs, Inc. completed a private placement financing, raising approximately $3 million in gross proceeds. The company issued pre-funded warrants and common warrants to existing institutional investors. Net proceeds, estimated at $2.7 million after fees, will be used for working capital and general corporate purposes.

GeoVax Labs reported a net loss of $5.3 million for Q1 2026, a slight improvement from $5.4 million in Q1 2025, with revenue dropping to zero due to the termination of a BARDA contract. The company highlighted significant progress in its GEO-MVA program, initiating a Phase 3 immunobridging clinical study under an EMA-aligned expedited regulatory pathway. GeoVax also advanced its Gedeptin immuno-oncology platform, securing an exclusive license agreement for combination therapies.

GeoVax Labs, Inc. reported a net loss of $(5.26) million for the first quarter of 2026, with cash and cash equivalents falling to $1.27 million. The company's existing cash resources are projected to last only until June 2026, raising substantial doubt about its ability to continue as a going concern. Revenue from government contracts ceased in Q1 2026, while the company continued to raise capital through stock and warrant offerings, providing $1.72 million in financing activities.

GeoVax Labs, Inc. entered into a warrant inducement transaction with existing institutional investors. This involved the immediate exercise of existing warrants to purchase 501,144 shares of common stock, generating approximately $595,000 in gross proceeds. In consideration, the company will issue new unregistered warrants to purchase up to 1,002,288 shares of common stock at an exercise price of $1.65 per share, exercisable upon stockholder approval. The net proceeds are intended for working capital and other general corporate purposes.

GeoVax Labs, Inc. will hold its Annual Meeting of Stockholders on June 17, 2026, where shareholders will vote on several key proposals. These include the election of seven directors and the ratification of Wipfli LLP as the independent registered public accounting firm for fiscal year 2026. The company is also seeking approval for the issuance of up to 865,804 shares and 1,269,316 shares upon the exercise of February 2026 and March 2026 common stock purchase warrants, respectively, which could lead to significant dilution. Additionally, advisory votes on executive compensation and the frequency of future compensation votes will be held.

GeoVax Labs, Inc. announced the issuance of a press release on April 15, 2026, detailing its financial results of operations for the fiscal year ended December 31, 2025. The full press release, which contains the comprehensive financial data, is included as an exhibit to this Current Report on Form 8-K.